Skip to content

Allograft Transplantation in the Treatment of Osteoarthritis of the Metatarsophalangeal (MTP) Joint of the Great Toe

Allograft Knee Meniscal Transplantation in the Treatment of Osteoarthritis of the Metatarsophalangeal (MTP) Joint of the Great Toe

Status
Completed
Phases
Phase 3
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01673347
Acronym
MTP
Enrollment
24
Registered
2012-08-28
Start date
2010-09-30
Completion date
2017-03-10
Last updated
2017-05-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Osteoarthritis

Keywords

allograft, great toe

Brief summary

Using the concept of an implant acting as a spacer and stabilizer, the proposed study will evaluate the use of allograft knee meniscus in the treatment of MTP joint osteoarthritis of the great toe.

Detailed description

A variety of surgical procedures have been developed for the treatment of MTP joint osteoarthritis of the great toe. Using the concept of an implant acting as a spacer and stabilizer, the proposed study will evaluate the use of allograft knee meniscus in the treatment of MTP joint osteoarthritis of the great toe. Patients will be evaluated for pain and range of motion at 3-months, 6-months, 1-year, 2-years, 3-years, 4-years, and 5-years postoperatively or until allograft failure. Stability of the allograft will be evaluated by the surgeon at these time points per radiographic imaging.

Interventions

Meniscal allograft

Sponsors

Musculoskeletal Transplant Foundation
CollaboratorOTHER
Paul Fortin, MD
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* symptomatic of stage 3 osteoarthritis of the great toe * symptoms recalcitrant to nonoperative management as determined clinically by the principal investigator

Exclusion criteria

* diabetes mellitus * kidney insufficiency * oa in the adjacent joints * malignancy with in the past 10 yrs * minors (\< 18 yrs of age) * pregnant women and fetus * mentally disabled or cognitively impaired individuals

Design outcomes

Primary

MeasureTime frameDescription
Allograft Stability5-years postoperativeEvaluation of the MTP joint space as determined by radiographic imaging. Count of participants maintaining adequate spacing and alignment as evaluated by the surgeon.

Secondary

MeasureTime frameDescription
Pain3-months postoperativePain scored on Visual Analog Scale 0-10; 0 = no pain, 10 = worst pain
Range of Motion Plantarflexion3-months postoperativeRange of Motion Plantarflexion
Range of Motion Dorsiflexion3-months postoperativeRange of Motion Dorsiflexion

Countries

United States

Participant flow

Participants by arm

ArmCount
MENISCAL ALLOGRAFT
The meniscal allograft is taken from the meniscal knee joint and implanted surgically in to the great toe. Meniscal Allograft: Meniscal allograft
24
Total24

Withdrawals & dropouts

PeriodReasonFG000
Overall Studyfailure of allograft7

Baseline characteristics

CharacteristicMENISCAL ALLOGRAFT
Age, Continuous55 years
STANDARD_DEVIATION 7.12
BMI25.27 kg/m2
STANDARD_DEVIATION 4.33
Race (NIH/OMB)
American Indian or Alaska Native
0 Participants
Race (NIH/OMB)
Asian
0 Participants
Race (NIH/OMB)
Black or African American
0 Participants
Race (NIH/OMB)
More than one race
0 Participants
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
0 Participants
Race (NIH/OMB)
Unknown or Not Reported
0 Participants
Race (NIH/OMB)
White
24 Participants
Sex: Female, Male
Female
21 Participants
Sex: Female, Male
Male
3 Participants

Adverse events

Event typeEG000
affected / at risk
deaths
Total, all-cause mortality
0 / 24
other
Total, other adverse events
7 / 24
serious
Total, serious adverse events
0 / 24

Outcome results

Primary

Allograft Stability

Evaluation of the MTP joint space as determined by radiographic imaging. Count of participants maintaining adequate spacing and alignment as evaluated by the surgeon.

Time frame: 5-years postoperative

Population: Study terminated prior to 5-year endpoint, no participants evaluated

ArmMeasureValue
MENISCAL ALLOGRAFTAllograft Stability0
Secondary

Pain

Pain scored on Visual Analog Scale 0-10; 0 = no pain, 10 = worst pain

Time frame: 3-months postoperative

Population: 17 participants available to analyze at 3 months due to early allograft failure in 7 participants

ArmMeasureValue (MEAN)Dispersion
MENISCAL ALLOGRAFTPain2.65 units on a scaleStandard Deviation 2.13
Secondary

Range of Motion Dorsiflexion

Range of Motion Dorsiflexion

Time frame: 3-months postoperative

Population: 17 participants available to analyze at 3 months due to early allograft failure in 7 participants

ArmMeasureValue (MEAN)Dispersion
MENISCAL ALLOGRAFTRange of Motion Dorsiflexion40 degreesStandard Deviation 15.86
Secondary

Range of Motion Plantarflexion

Range of Motion Plantarflexion

Time frame: 3-months postoperative

Population: 17 participants available to analyze at 3 months due to early allograft failure in 7 participants

ArmMeasureValue (MEAN)Dispersion
MENISCAL ALLOGRAFTRange of Motion Plantarflexion20 degreesStandard Deviation 8.13

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026